JP4271142B2 - 1−ジメチルアミノ−3−(3−メトキシ−フェニル)−2−メチル−ペンタン−3−オール及び3−(3−ジメチルアミノ−1−エチル−1−ヒドロキシ−2−メチル−プロピル)−フェノールの有効物質塩及びエステル - Google Patents
1−ジメチルアミノ−3−(3−メトキシ−フェニル)−2−メチル−ペンタン−3−オール及び3−(3−ジメチルアミノ−1−エチル−1−ヒドロキシ−2−メチル−プロピル)−フェノールの有効物質塩及びエステル Download PDFInfo
- Publication number
- JP4271142B2 JP4271142B2 JP2004510769A JP2004510769A JP4271142B2 JP 4271142 B2 JP4271142 B2 JP 4271142B2 JP 2004510769 A JP2004510769 A JP 2004510769A JP 2004510769 A JP2004510769 A JP 2004510769A JP 4271142 B2 JP4271142 B2 JP 4271142B2
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- ester
- dimethylamino
- methyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC*(c1c(C)cccc1)c(c(N)ccc1)c1N Chemical compound CCC*(c1c(C)cccc1)c(c(N)ccc1)c1N 0.000 description 5
- INCYIBYTUZLVLV-BXUZGUMPSA-N CC[C@@]([C@H](C)CN(C)C)(c1cccc(O)c1)O Chemical compound CC[C@@]([C@H](C)CN(C)C)(c1cccc(O)c1)O INCYIBYTUZLVLV-BXUZGUMPSA-N 0.000 description 1
- KNFJNBCHHLFPCH-JTMIDMFHSA-N CC[C@@]([C@H](C)CN(C)Cc1c(c(CC(O)=O)c(C)[n]2C(c(cc3)ccc3Cl)=O)c2ccc1OC)(c1cccc(OC)c1)O Chemical compound CC[C@@]([C@H](C)CN(C)Cc1c(c(CC(O)=O)c(C)[n]2C(c(cc3)ccc3Cl)=O)c2ccc1OC)(c1cccc(OC)c1)O KNFJNBCHHLFPCH-JTMIDMFHSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N C[C@H](C(O)=O)c(cc1)cc(cc2)c1cc2OC Chemical compound C[C@H](C(O)=O)c(cc1)cc(cc2)c1cc2OC CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- QNWKYDCMXQSXQB-UHFFFAOYSA-N Cc(cc1)cc(N)c1-c1ccccc1 Chemical compound Cc(cc1)cc(N)c1-c1ccccc1 QNWKYDCMXQSXQB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/62—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
- C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C219/30—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
- C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/28—Two oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/28—Two oxygen or sulfur atoms
- C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
- C07D231/32—Oxygen atoms
- C07D231/34—Oxygen atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
1-ジメチルアミノ-3-(3-メトキシ- フェニル)-2-メチル- ペンタン-3- オール及び下記の群から選ばれる有効物質:
・ イブプロフェン,
・ (S)(+)イブプロフェン,
・ (S)(+)ナプロキセン,
・ ジクロフェナック,
・ アセチルサリチル酸,
・ ジピロン,
・ インドメタジン,
・ ケトプロフェン,
・ イソキシカム,
・ フルルビプロフェン,
・ ピロキシカム又は
・ フェニルブタゾン
から形成される1-ジメチルアミノ-3-(3-メトキシ- フェニル)-2-メチル- ペンタン-3- オールの有効物質塩である。
3-(3- ジメチルアミノ-1- エチル-1- ヒドロキシ-2- メチル- プロピル)-フェノール及び下記の群から選ばれる有効物質:
・ イブプロフェン,
・ (S)(+)イブプロフェン,
・ (S)(+)ナプロキセン,
・ ジクロフェナック,
・ アセチルサリチル酸,
・ ジピロン,
・ インドメタジン,
・ ケトプロフェン,
・ イソキシカム,
・ フルルビプロフェン,
・ ピロキシカム又は
・ フェニルブタゾン
から形成される3-(3- ジメチルアミノ-1- エチル-1- ヒドロキシ-2- メチル- プロピル)-フェノールの有効物質塩である。
示された形に又はその酸又はその塩基の形に又はその塩, 特にその生理学的に許容し得る塩の形に,又はその溶媒和、特にその水和物の形にある、式 I
・ イブプロフェン,
・ (S)(+)イブプロフェン,
・ (S)(+)ナプロキセン,
・ インドメタジン,
・ ジクロフェナック,
・ ジピロン,
・ フルルビプロフェン,
・ ケトプロフェン又は
・ アセチルサリチル酸
から選ばれる。}
で表わされる3-(3- ジメチルアミノ-1- エチル-1- ヒドロキシ-2- メチル- プロピル)-フェノールのエステルである。
示された形に又はその酸又はその塩基の形に又はその塩, 特にその生理学的に許容し得る塩の形に,又はその溶媒和、特にその水和物の形にある、式 II
そしてR2 はH 又はC1-3-アルキル(これは飽和又は不飽和の、置換されていないか又は1回以上置換されている)から選ばれる。}
で表わされるエステルである。
示された形に又はその酸又はその塩基の形に又はその塩, 特にその生理学的に許容し得る塩の形に,又はその溶媒和、特にその水和物の形にある、式III
で表わされるエステルである。
示された形に又はその酸又はその塩基の形に又はその塩, 特にその生理学的に許容し得る塩の形に,又はその溶媒和、特にその水和物の形にある、式 IV
R5 はH 又はC1-3-アルキル(これは飽和又は不飽和の、置換されていないか又は1回以上置換されている)から選ばれる。}
で表わされるエステルである。
驚くべきことに、上記物質は増加した尿意及び尿失禁において重要である特定の生理学的パラメーター、たとえば膨張圧、内部収縮間隔又はリズミカルな膀胱収縮の減少及び(又は)膀胱容量に明らかに好ましい影響を与えることが明らかとなった。これらの変化の個々のそれぞれは該当する患者の症状病型において明らかな軽減を示すことができる。
基R23 及びR24は同一か又は相違し、H, C1-10-アルキル基、好ましくはC1-6-アルキル基、アリール基、又はヘテロアリール基を意味するか又はC1-3-アルキレン基を介して結合するアリール基又はヘテロアリール基を意味し、但しアリール基及びヘテロアリール基それ自体はアリール基又はヘテロアリール基で置換されてはならない;
又は
基R23 及びR24は一緒になってCH2CH2OCH2CH2, CH2CH2NR25CH2CH2 又は (CH2)3-6を意味し、
基R25 はH、C1-10-アルキル基、好ましくはC1-6-アルキル基、アリール基、又はヘテロアリール基を意味するか又はC1-3-アルキルを介して結合する, 飽和又は不飽和の、又はC1-3-アルキレン基を介して結合するアリール基又はヘテロアリール基を意味し、但しアリール基及びヘテロアリール基それ自体はアリール基又はヘテロアリール基によって置換されてはならない。
有効性について試験される化合物のリストは次の通りである:
Ishizuka等 ((1997), Naunyn-Schmiedeberg ’s Arch. Pharmacol. 355: 787 - 793) の方法にしたがって実験未使用の雌性スプラーグダーレー(Sprague-Dawley)ラットの膀胱内圧測定試験を行う。膀胱カレーテル及び静脈カレーテルの注入3 日後意識のある状態で自由に動けるラットを調べる。膀胱カテーテルを圧力受容器及び注入ポンプに連結する。動物を尿容量の測定を可能にする物質代謝ケージ中に置く。生理食塩溶液を空の膀胱に注入し(10ml/h)、膀胱内圧及び排尿容量を連続的に記録する。安定化段階の後、正常の再産生可能な排尿サイクルによって特徴づけられる20分の様相を記録する。詳細には下記のパラメーターを測定する:
・膨張圧(限界圧threshold pressure TP、排尿直前の膀胱内圧)、
・膀胱容積(bladder capacity BC、上記排尿後の残存容量+充満段階の間注入された溶液の容量)、
・内部収縮間隔(inter-contraction interval (ICI), 排尿間の時間間隔)。
原則として、次の化合物:
(+) (2R,3R)-3-(3- ジメチルアミノ-1-エチル-1-ヒドロキシ-2-メチル-プロピル)-フェノールをM1 として、そして
(+)-(2R,3R)-1- ジメチルアミノ-3-(3-メトキシ-フェニル)-2-メチル-ペンタン-3-オールをM0 として表記する。
反応式:(下記式中、WIRKSTOFF=有効物質、Mol. Wt.=分子量)
フルルビプロフェンとのエステル
収量: 270 mg
分析: LC-MS
1H NMR
融点: 128,3 °C
例32:
ジクロフェナックとのエステル
1,8 mmol 物質 930 mg
2,2 mmol トリメチルクロロシラン 278 ml 1,2 eq
エーテル
アセトン
塩基をエーテル中に取り、数滴のアセトンで溶解させる。氷冷却下で、トリメチルクロロシランを添加する。直ちに無色の沈殿が析出する。一晩、攪拌する。
収量: 680 mg
分析: LC-MS 1H NMR FR2
融点: 111,9 °C
例33 〜 39記載の次のエステルを前述のように(例 30参照)製造する。
イブプロフェンとのエステル
(S)(+)-イブプロフェンとのエステル
(S)(+)-ナプロキセンとのエステル
インドメタジンとのエステル
ジピロンとのエステル
ケトプロフェンとのエステル
アセチルサリチル酸とのエステル
M1の塩の一般製造方法
M1と (s)(+) イブプロフェンの塩
M1 とフルルビプロフェンの塩
例 43
M1とイブプロフェンの塩
M1 と(S)(+) ナプロキセンの塩
M1とジクロフェナックの塩
M1とアセチルサリチル酸の塩
M1とジピロンの塩
M1とインドメタジンの塩
M1とケトプロフェンの塩
M1とイソキシカムの塩
M1 とピロキシカムの塩
M1とフェニルブタゾンの塩
M0 とジクロフェナックの塩
M0 とインドメタジンの塩
M0とイブプロフェンの塩
M0 と(s)(+) イブプロフェンの塩
M0と(S)(+) ナプロキセンの塩
M0とアセチルサリチル酸の塩
M0とジピロンの塩
M0とケトプロフェンの塩
M0とイソキシカムの塩
M0とフルルビプロフェンの塩
M0とピロキシカムの塩
M0とフェニルブタゾンの塩
1-ジメチルアミノ-3-(3-メトキシ- フェニル)-2-メチル- ペンタン-3- オールとジクロフェナックの有効物質塩( 例61 ) 20 gを注射用水1 リットルに室温で溶解させ、ついでNaClの添加によって等張条件に調整する。
Claims (16)
- ラセミ化合物又は純粋な立体異性体の形にあるか , あるいは立体異性体の混合物の形にある、1-ジメチルアミノ-3-(3-メトキシ-フェニル)-2-メチル-ペンタン-3-オール及び下記の群から選ばれる有効物質:
・ イブプロフェン,
・ (S)(+) イブプロフェン,
・ (S)(+) ナプロキセン,
・ ジクロフェナック,
・ アセチルサリチル酸,
・ ジピロン,
・ インドメタジン,
・ ケトプロフェン,
・ イソキシカム,
・ フルルビプロフェン,
・ ピロキシカム又は
・ フェニルブタゾン
から形成される、1-ジメチルアミノ-3-(3-メトキシ-フェニル)-2-メチル-ペンタン-3-オールの有効物質塩。 - (+)-(2R,3R)-1-ジメチルアミノ-3-(3-メトキシ-フェニル)-2-メチル-ペンタン-3-オールの有効物質塩である、請求項1記載の有効物質塩。
- ラセミ化合物又は純粋な立体異性体の形にあるか , あるいは立体異性体の混合物の形にある、
3-(3-ジメチルアミノ-1-エチル-1-ヒドロキシ-2-メチル-プロピル)-フェノール及び下記の群から選ばれる有効物質:
・ イブプロフェン,
・ (S)(+) イブプロフェン,
・ (S)(+) ナプロキセン,
・ ジクロフェナック,
・ アセチルサリチル酸,
・ ジピロン,
・ インドメタジン,
・ ケトプロフェン,
・ イソキシカム,
・ フルルビプロフェン,
・ ピロキシカム又は
・ フェニルブタゾン
から形成される、3-(3-ジメチルアミノ-1-エチル-1-ヒドロキシ-2-メチル-プロピル)-フェノールの有効物質塩。 - (+)-(2R,3R)-3-(3-ジメチルアミノ-1-エチル-1-ヒドロキシ-2-メチル-プロピル)-フェノールの有効物質塩である、請求項3記載の有効物質塩。
- ラセミ化合物又は純粋な立体異性体の形にあるか , 又は立体異性体の混合物の形にあるか、又はその生理学的に許容し得る塩の形にある、式 I
・ イブプロフェン (下記式A),
・ アセチルサリチル酸(下記式J)
で表わされる3-(3-ジメチルアミノ-1-エチル-1-ヒドロキシ-2-メチル-プロピル)-フェノールのエステル。 - 請求項1〜4のいずれか1つに記載の有効物質塩あるいは請求項5〜12のいずれか1つに記載のエステルの少なくとも1種並びに生理学的に許容し得る添加物及び(又は) 助剤を含む、医薬。
- 請求項1〜4のいずれか1つに記載の有効物質塩又は請求項5〜12のいずれか1つに記載のエステルを、増加した尿意又は尿失禁の治療用医薬の製造に使用する方法。
- 請求項1〜4のいずれか1つに記載の有効物質塩又は請求項5〜12のいずれか1つに記載のエステルを、痛みの治療用医薬の製造に使用する方法。
- 痛みが、慢性痛 , 内臓性痛 , 神経障害性痛又は急性痛又は炎症性痛から選ばれる、請求項15記載の使用する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10225315A DE10225315A1 (de) | 2002-06-06 | 2002-06-06 | Wirkstoffsalze und Ester von 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl- pentan-3-ol und 3-(3-Dimethylamino-1-ethyl-1-hydroxy-2-methyl- propyl)-phenol |
PCT/EP2003/005971 WO2003103650A1 (de) | 2002-06-06 | 2003-06-06 | Wirkstoffsalze und ester von 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol und 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005538956A JP2005538956A (ja) | 2005-12-22 |
JP2005538956A5 JP2005538956A5 (ja) | 2009-01-29 |
JP4271142B2 true JP4271142B2 (ja) | 2009-06-03 |
Family
ID=29594314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004510769A Expired - Fee Related JP4271142B2 (ja) | 2002-06-06 | 2003-06-06 | 1−ジメチルアミノ−3−(3−メトキシ−フェニル)−2−メチル−ペンタン−3−オール及び3−(3−ジメチルアミノ−1−エチル−1−ヒドロキシ−2−メチル−プロピル)−フェノールの有効物質塩及びエステル |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1509216B1 (ja) |
JP (1) | JP4271142B2 (ja) |
AR (1) | AR040252A1 (ja) |
AT (1) | ATE394098T1 (ja) |
AU (1) | AU2003238478A1 (ja) |
DE (2) | DE10225315A1 (ja) |
ES (1) | ES2305465T3 (ja) |
PE (1) | PE20040540A1 (ja) |
WO (1) | WO2003103650A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1562567T (pt) * | 2002-11-22 | 2017-08-24 | Gruenenthal Gmbh | Combinação de analgésicos selecionados e inibidores da cox-ii |
DE10356112A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
US8552219B2 (en) | 2010-09-20 | 2013-10-08 | Ind-Swift Laboratories Limited | Process for preparing L-phenyl-3-dimethylaminopropane derivative |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
DE19609847A1 (de) * | 1996-03-13 | 1997-09-18 | Gruenenthal Gmbh | Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe |
DE10059412A1 (de) * | 2000-11-30 | 2002-06-13 | Gruenenthal Gmbh | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz |
DE10108123A1 (de) * | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Wirkstoffkombination |
DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
-
2002
- 2002-06-06 DE DE10225315A patent/DE10225315A1/de not_active Withdrawn
-
2003
- 2003-06-06 AU AU2003238478A patent/AU2003238478A1/en not_active Abandoned
- 2003-06-06 DE DE50309786T patent/DE50309786D1/de not_active Expired - Lifetime
- 2003-06-06 EP EP03732544A patent/EP1509216B1/de not_active Expired - Lifetime
- 2003-06-06 ES ES03732544T patent/ES2305465T3/es not_active Expired - Lifetime
- 2003-06-06 JP JP2004510769A patent/JP4271142B2/ja not_active Expired - Fee Related
- 2003-06-06 PE PE2003000567A patent/PE20040540A1/es not_active Application Discontinuation
- 2003-06-06 AT AT03732544T patent/ATE394098T1/de active
- 2003-06-06 WO PCT/EP2003/005971 patent/WO2003103650A1/de active IP Right Grant
- 2003-06-06 AR ARP030102036A patent/AR040252A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1509216B1 (de) | 2008-05-07 |
PE20040540A1 (es) | 2004-09-09 |
JP2005538956A (ja) | 2005-12-22 |
DE50309786D1 (de) | 2008-06-19 |
AU2003238478A1 (en) | 2003-12-22 |
WO2003103650A1 (de) | 2003-12-18 |
EP1509216A1 (de) | 2005-03-02 |
DE10225315A1 (de) | 2003-12-24 |
ES2305465T3 (es) | 2008-11-01 |
AR040252A1 (es) | 2005-03-23 |
ATE394098T1 (de) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8946290B2 (en) | Combination of selected opioids with muscarine antagonists for treating urinary incontinence | |
JP2003510350A (ja) | (+)−トラマドール、o−デメチルトラマドール又は(+)−o−デメチルトラマドール、o−デスメチル−n−モノ−デスメチル−トラマドール又は(+)−o−デスメチル−n−モノ−デスメチル−トラマドールを尿失禁の治療に使用する方法 | |
US20060194860A1 (en) | Pharmaceutical compositions containing aryl or heteroaryl azolylcarbinol compounds | |
DE10224107A1 (de) | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz | |
RU2286768C2 (ru) | Применение 1-фенил-3-диметиламинопропановых соединений для терапии недержания мочи | |
JP5993303B2 (ja) | リウマチ性痛を治療するための1−フェニル−3−ジメチルアミノプロパン化合物の使用 | |
JP4271142B2 (ja) | 1−ジメチルアミノ−3−(3−メトキシ−フェニル)−2−メチル−ペンタン−3−オール及び3−(3−ジメチルアミノ−1−エチル−1−ヒドロキシ−2−メチル−プロピル)−フェノールの有効物質塩及びエステル | |
US7550624B2 (en) | Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol and methods of using same | |
JP4284065B2 (ja) | 置換された6−ジメチルアミノメチル−1−フェニル−シクロヘキサン化合物を尿失禁の治療に使用する方法 | |
RU2280444C2 (ru) | Применение 6-диметиламинометил-1-фенилциклогексановых соединений для терапии недержания мочи | |
EP1634598A1 (en) | Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | |
US20050137194A1 (en) | Combination of selected opioids with other active compounds for treatment of urinary incontinence | |
DE10224624A1 (de) | Metabolite und Prodrugs von 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080909 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20081208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090210 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090224 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120306 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4271142 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120306 Year of fee payment: 3 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120306 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130306 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130306 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140306 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |